Sign Up for a Free Account
  • Updated 06.09.2021
  • Released 07.11.1994
  • Expires For CME 06.09.2024

Wilson disease

Introduction

Overview

The history of Wilson disease is a microcosm of the history of neurology, beginning with seminal clinical observations by the man whose name the disease bears, followed by pioneering work translating copper deficiencies in sheep to human treatment, and continuing on to identification of causative gene mutations. Amongst neurodegenerative disease, it is unusual in that treatments can prevent and cure Wilson disease if they are given appropriately. Despite a long history, Wilson disease remains an important disease that is usually misdiagnosed. Misdiagnosis and delay in treatment are clinically relevant because if left untreated, Wilson disease progresses to hepatic failure or severe neurologic disability and death. Those adequately treated have a normal life span. In this article, the author discusses the neurologic features of Wilson disease, its diagnosis, and new treatment options.

Key points

• Wilson disease is caused by mutations in ATP7B that result in abnormal copper metabolism, and subsequent excess free copper is toxic.

• The most common clinical manifestations of neurologic Wilson disease include variable combinations of dysarthria, dystonia, tremor, and parkinsonism.

• Recognition of the disorder is important because effective treatment can prevent or improve disease features.

• The most useful screening procedure is a 24-hour urine copper test. In symptomatic Wilson disease the 24-hour urine copper is always elevated to a value greater than 100 µg per 24 hours (normal is 50 µg or less).

• The aim of treatment is to reduce the amount of toxic free copper. Currently available agents in the United States include zinc acetate and trientine. Clinical trials suggest tetrathiomolybdate may be the preferred agent for initial treatment for neurologic Wilson disease, but it is not currently FDA approved.

Historical note and terminology

The historical landmark paper in this disease was written in 1912 by Samuel Alexander Kinnier-Wilson, an American neurologist working at The National Hospital at Queen Square in London (64; 15). He described a neurologic disorder associated with progressive lenticular degeneration and cirrhosis of the liver that came later to be known as Wilson disease, or hepatolenticular degeneration. The disease described by Wilson was one dominated by juvenile age at onset with dystonia and contrasted from the form of disease described by Westpahl in 1883 as pseudosclerotic, which had a young adult age of onset and symptomatically consisted principally of tremor and dysarthria. Only later was parkinsonism recognized as a major clinical feature of Wilson disease. Kayser and Fleischer described the corneal copper deposits associated with the disease, which later became known as Kayser-Fleischer rings. Several authors have described excess copper deposition, but Cumings was the first to postulate an etiologic role for copper and suggested that chelation therapy might be of benefit. A low biliary excretion of copper was later shown to be responsible for a failure to regulate copper balance, and the disease was found to be inherited as an autosomal-recessive disorder. Landmarks in treatment have included the development of penicillamine, trientine, and zinc therapies (61). The gene for Wilson disease has been identified and an animal model of Wilson disease has provided insights into pathogenesis (11; 58; 65).

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com